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Abstracts
 
METHODS:
 
 Treatment patterns and probability distri-
butions for the Japanese Breast Cancer Treatment Model
(JBCTM) were identified and confirmed via a series of
meetings with a clinical expert panel and a study-specific
survey of practice patterns of over 500 Japanese breast
cancer physicians. Since no Japanese guidelines for evalu-
ating level-of-evidence data yet exist, guidelines from the
American Society of Clinical Oncology were used to
stratify the clinical usage and clinical outcomes data for
every drug. Consideration was given to disease stage and
treatment setting in assigning the level of evidence, and
nodal status, hormone receptor status, and menopausal
status were also considered. Costs were obtained from
government sources and hospital provider surveys and
validated by an expert panel.
RESULTS: The model features treatment pathways for
four breast cancer stages and resources and costs for ev-
ery treatment option in the model. In total, the model in-
cludes over 450 level-of-evidence references for more
than 60 drug treatments. The model can generate re-
sponses to an infinite number of queries regarding the
probabilities of receiving a particular treatment in a given
setting, cost per treatment, expected cost per patient, and
an estimate of cost-effectiveness with consideration given
to the evidence level associated with treatments.
CONCLUSIONS: To incorporate level-of-evidence data
into a comprehensive treatment model, level-of-evidence
guidelines can be applied to treatments in a given setting
and combined with published data, data from surveys,
and expert opinion to generate a valuable decision-mak-
ing tool. The treatment pathways, costs and cost-effec-
tiveness, and the evidence level associated with those
pathways can then be evaluated on the credibility of clin-
ical results.
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OBJECTIVE: Tiotropium is a new once daily bronchodi-
lator for the treatment of patients with Chronic Obstruc-
tive Pulmonary Disease (COPD). Treatment patterns in
COPD differ considerably between countries and resource
use in one country cannot be transferred to other countries
without adjustments. The aim of this study was to develop
a Markov model to transfer trial-based cost-effectiveness
data about tiotropium versus ipratropium, salmeterol and
existing therapy from one setting to another.
METHODS: Markov states were defined on the basis of
COPD severity (moderate A, moderate B and Severe ac-
cording to GOLD guidelines). Transition probabilities
and probabilities of experiencing a severe or non-severe
exacerbation were derived from three trial-based cost-
effectiveness analyses, which were performed in the
Netherlands, Belgium, the USA and in 18 other countries.
Resource use was distinguished into maintenance treat-
ment according to disease severity and treatment associ-
ated with exacerbations. The model allowed for country-
specific input of resource use and unit costs including the
probability and duration of hospitalization during an ex-
acerbation.
RESULTS: All costs other than the cost of study medica-
tion were consistently lower in tiotropium than in the
other three treatment arms, mainly because of the 13%
to 27% lower probability of experiencing a (severe) exac-
erbation. Costs in the US were approximately twice as
high as the costs in the Netherlands and Belgium. The
proportion of total costs due to hospitalization varied be-
tween 30% and 60%, depending on the treatment arm
and the country.
CONCLUSION: The difference between treatment
groups observed in the trials could be modeled entirely by
the monthly transition probabilities between disease
states and the probabilities of experiencing an exacerba-
tion in a given disease state. A Markov model in which
resource use depends on disease state and exacerbations,
irrespective of treatment group, is well suited to convert
trial-based pharmacoeconomic data in COPD to other
countries.
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OBJECTIVE: In a recent economic evaluation conducted
alongside an RCT, we encountered asymmetry in the time
horizons for effectiveness and cost outcomes. The effec-
tiveness variable was evaluated at the end of the trial, but
some hospitalizations that started during the RCT contin-
ued beyond the end of the trial period. This paper demon-
strates how estimates of cost-effectiveness ratios can be
very sensitive to this problem at the analysis stage.
METHODS: Medical care resource-use data were collected
prospectively in an RCT comparing two treatments for a
chronic condition characterized by acute episodes often re-
quiring hospitalization. A vector of country-specific unit
costs was used to convert resource consumption into mone-
tary values for the purpose of performing a cost-effective-
ness analysis. Effectiveness was measured as the number of
successfully treated patients (STPs) at the end of the six-
month trial. Cost-effectiveness acceptability curves (CEACs)
for analyses that include and exclude components of re-
source consumption beyond the trial are compared.
RESULTS: The incremental cost per STP is £10,008 if
the components of resource use beyond trial are excluded
and £27,200 if included. This result is due to the effect
